Media coverage about icad inc. (NASDAQ:ICAD) has been trending somewhat positive recently, according to Accern. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. icad inc. earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news articles about the technology company an impact score of 45.6784446180205 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
icad inc. (ICAD) traded up 2.43% during midday trading on Friday, reaching $4.64. The company’s stock had a trading volume of 30,695 shares. The stock’s 50 day moving average is $3.98 and its 200 day moving average is $4.36. The stock’s market cap is $77.00 million. icad inc. has a 12-month low of $2.82 and a 12-month high of $6.07.
icad inc. (NASDAQ:ICAD) last released its earnings results on Tuesday, August 8th. The technology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.03. The business had revenue of $6.41 million for the quarter, compared to analyst estimates of $6.41 million. icad inc. had a negative return on equity of 44.39% and a negative net margin of 34.74%. Analysts anticipate that icad inc. will post ($0.54) earnings per share for the current year.
A number of brokerages recently commented on ICAD. ValuEngine upgraded icad inc. from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd. Laidlaw reiterated a “buy” rating and issued a $11.00 target price on shares of icad inc. in a research report on Tuesday, July 25th.
In other icad inc. news, Director Dr Lawrence Howard purchased 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were purchased at an average cost of $3.33 per share, for a total transaction of $33,300.00. Following the completion of the purchase, the director now directly owns 488,022 shares in the company, valued at $1,625,113.26. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 19.10% of the stock is owned by insiders.
About icad inc.
iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).
Receive News & Ratings for icad inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for icad inc. and related companies with MarketBeat.com's FREE daily email newsletter.